Abstract:A typographical error appeared in the author affiliation titled “Investigation of the Apoptosis Inducing and β-catenin Silencing by Tetradentate Schiff Base Zinc(II) Complex on the T-47D Breast Cancer Cells”, published in Anti-Cancer Agents in Medicinal Chemistry, 2023, 23(15) [1]. Details of the error and a correction are provided here. Original: Author Affiliation: 2Department of Breast Medicine, Cancer Hospital Chinese Academy of Medical Science, Liaoning Provincial Cancer Hospital, Shenyang, Liaoning, 110042, China Corrected: Author Affiliation: 2Department of Breast Medicine, Cancer Hospital of China Medical University, Liaoning Cancer Hospital, Shenyang, China We regret the error and apologize to readers. The original article can be found online at https://www.eurekaselect.com/article/131718

Erratum: Author correction to 'Real-time SERS monitoring anticancer drug release along with SERS/MR imaging for pH-sensitive chemo-phototherapy' [Acta Pharm Sin B 13 (2023) 1303-1317]

Erratum: Author Correction to "Tumor-Microenvironment Activated Duplex Genome-Editing Nanoprodrug for Sensitized Near-Infrared Titania Phototherapy" [acta Pharm Sin B (2022) 4224-4234].

Correction: Corrigendum: Quantitative real-time imaging of glutathione

Author Correction to “Tumor-Microenvironment Activated Duplex Genome-Editing Nanoprodrug for Sensitized Near-Infrared Titania Phototherapy” [acta Pharm Sin B 12 (2022) 4224–4234]

Author correction to “Coordinated regulation of BACH1 and mitochondrial metabolism through tumor targeted self-assembled nanoparticles for effective triple negative breast cancer combination therapy” [Acta Pharmaceutica Sinica B 12 (2022) 3934–3951]

Correction: Recent progress in SERS monitoring of photocatalytic reactions

Erratum to “Near-infrared responsive 5-fluorouracil and indocyanine green loaded MPEG-PCL nanoparticle integrated with dissolvable microneedle for skin cancer therapy” [Bioact. Mater. 5 (2020) 542–552]

Correction: Facile Preparation of Phospholipid-Amorphous Calcium Carbonate Hybrid Nanoparticles: Toward Controllable Burst Drug Release and Enhanced Tumor Penetration.

Author correction to “Coordinated regulation of BACH1 and mitochondrial metabolism through tumor targeted self-assembled nanoparticles for effective triple negative breast cancer combination therapy” [Acta Pharmaceutica Sinica B (2022) 12 (10) 3934–3951]

Erratum: Author correction to "Gas-propelled nanomotors alleviate colitis through the regulation of intestinal immunoenvironment-hematopexis-microbiota circuits" [Acta Pharm Sin B 14 (2024) 2732-2747]

Correction: Radiopharmaceutical-activated silicon naphthalocyanine nanoparticles towards tumor photodynamic therapy

Erratum: Author correction to 'Co-delivery of nigericin and decitabine using hexahistidine-metal nanocarriers for pyroptosis-induced immunotherapeutics' [Acta Pharm Sin B 12 (2022) 4458-4471]

Nanosonosensitizers for Highly Efficient Sonodynamic Cancer Theranostics: Erratum

Correction: FDPP–HA as a theranostic agent for cancer-targeted fluorescence imaging and photodynamic therapy

Corrigendum to: Investigation of the Apoptosis Inducing and β-catenin Silencing by Tetradentate Schiff Base Zinc(II) Complex on the T-47D Breast Cancer Cells

Erratum: Author correction to 'VEGFR2-targeted antibody fused with IFNamut regulates the tumor microenvironment of colorectal cancer and exhibits potent anti-tumor and anti-metastasis activity' [Acta Pharm Sin B 11 (2021) 420-433]

Tumor Theranostics of Transition Metal Ions Loaded Polyaminopyrrole Nanoparticles: Erratum

Correction: Tumor-targeting, enzyme-activated nanoparticles for simultaneous cancer diagnosis and photodynamic therapy

Correction: Engineering Cu 2− x S-conjugated upconverting nanocomposites for NIR-II light-induced enhanced chemodynamic/photothermal therapy of cancer

Erratum: Wu, B.; Et Al. Metal–Organic Framework-Based Chemo-Photothermal Combinational System for Precise, Rapid, and Efficient Antibacterial Therapeutics. Pharmaceutics 2019, 11, 463

Author correction to ‘Discovery and identification of EIF2AK2 as a direct key target of berberine for anti-inflammatory effects’ [Acta Pharmaceutica Sinica B 13 (2023) 2138–2151]